184 related articles for article (PubMed ID: 10727604)
1. Experimental radioimmunotherapy.
Buchsbaum DJ
Semin Radiat Oncol; 2000 Apr; 10(2):156-67. PubMed ID: 10727604
[TBL] [Abstract][Full Text] [Related]
2. Overview of studies on experimental radioimmunotherapy.
Knox SJ
Cancer Res; 1995 Dec; 55(23 Suppl):5832s-5836s. PubMed ID: 7493355
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on metals-based radioimmunotherapy (RIT): moving forward.
White JM; Escorcia FE; Viola NT
Theranostics; 2021; 11(13):6293-6314. PubMed ID: 33995659
[TBL] [Abstract][Full Text] [Related]
4. Combined modality radioimmunotherapy. Promise and peril.
Burke PA; DeNardo SJ; Miers LA; Kukis DL; DeNardo GL
Cancer; 2002 Feb; 94(4 Suppl):1320-31. PubMed ID: 11877763
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
6. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
7. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
8. Protein targeting constructs in alpha therapy.
Olafsen T; Elgqvist J; Wu AM
Curr Radiopharm; 2011 Jul; 4(3):197-213. PubMed ID: 22201709
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
10. Selection of reagents for human radioimmunotherapy.
Vriesendorp HM; Quadri SM; Stinson RL; Onyekwere OC; Shao Y; Klein JL; Leichner PK; Williams JR
Int J Radiat Oncol Biol Phys; 1992; 22(1):37-45. PubMed ID: 1727128
[TBL] [Abstract][Full Text] [Related]
11. Experimental approaches to increase radiolabeled antibody localization in tumors.
Buchsbaum DJ
Cancer Res; 1995 Dec; 55(23 Suppl):5729s-5732s. PubMed ID: 7493336
[TBL] [Abstract][Full Text] [Related]
12. The new golden era for radioimmunotherapy: not just for lymphomas anymore.
Tomblyn MB; Katin MJ; Wallner PE
Cancer Control; 2013 Jan; 20(1):60-71. PubMed ID: 23302908
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
14. Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies.
Bethge WA; Sandmaier BM
Semin Oncol; 2004 Feb; 31(1):68-82. PubMed ID: 14970939
[TBL] [Abstract][Full Text] [Related]
15. Status of radioimmunotherapy in the new millennium.
Imam SK
Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488
[TBL] [Abstract][Full Text] [Related]
16. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
17. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma.
Zeng ZC; Tang ZY; Yang BH; Liu KD; Wu ZQ; Fan J; Qin LX; Sun HC; Zhou J; Jiang GL
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1657-68. PubMed ID: 12458401
[TBL] [Abstract][Full Text] [Related]
18. Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours.
Eriksson D; Joniani HM; Sheikholvaezin A; Löfroth PO; Johansson L; Riklund Ahlström K; Stigbrand T
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):895-906. PubMed ID: 12721768
[TBL] [Abstract][Full Text] [Related]
19. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
[TBL] [Abstract][Full Text] [Related]
20. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
